After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Chronic obstructive pulmonary disease (COPD) can result from chronic bronchitis ... These symptoms usually worsen over time without treatment. You can also develop conditions like irregular ...

New Study Shows Promising Results for COPD Treatment Nov. 20 ... June 11, 2024 — Chronic lung diseases are often accelerated and exacerbated by polymicrobial infections. An international ...

New Study Shows Promising Results for COPD Treatment Nov. 20 ... Sep. 26, 2024 — What factors lead to chronic respiratory disease? Researchers investigated this question using health data ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

The growing prevalence of COPD among women can be attributed to a combination of biological, environmental, and societal ...

“Preventing unnecessary exposure to air pollution and consistently wearing masks in high-risk environments can significantly ...

The following is a summary of “Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

The Zephyr Valve procedure is a minimally invasive treatment for severe or very severe COPD and emphysema. It offers an alternative to highly invasive options like lung transplants, which carry ...